Abstract
Molecular profiling of cancers can potentially yield novel gene markers of therapeutic prediction, which would aid our ability to tailor targeted therapy regimens specific to each patient. Public data from gene expression profiling may yield clues as to what oncogenic signaling pathways are deregulated in cancers, and what drugs may effectively counteract the aberrant gene regulation patterns observed. Data are also available on panels of cancer cell lines, which have been both profiled at the gene expression level and extensively characterized for drug responses, allowing us to identify geneto- drug correlations. Profiling tumors from patients undergoing adjuvant or neoadjuvant drug treatment can also yield markers of therapeutic response. In this review, we will examine recent studies aimed at our eventually being able to use the molecular profile of a tumor to predict drug response. The profiling data from these studies is publicly available, and can be re-examined by researchers with different questions in mind, offering us a large number of biomarker candidates that could potentially be tested in the clinical setting.
Keywords: Gene expression profiling, oncogenic signatures, drug response prediction, molecular profile of a tumor, gene regulation, CONNECTIVITY MAP, oncogenic signaling pathways, ER+) breast tumors, biomarkers, gene transcription.
Current Drug Targets
Title:Molecular Classification and Drug Response Prediction in Cancer
Volume: 13 Issue: 12
Author(s): Chad J. Creighton
Affiliation:
Keywords: Gene expression profiling, oncogenic signatures, drug response prediction, molecular profile of a tumor, gene regulation, CONNECTIVITY MAP, oncogenic signaling pathways, ER+) breast tumors, biomarkers, gene transcription.
Abstract: Molecular profiling of cancers can potentially yield novel gene markers of therapeutic prediction, which would aid our ability to tailor targeted therapy regimens specific to each patient. Public data from gene expression profiling may yield clues as to what oncogenic signaling pathways are deregulated in cancers, and what drugs may effectively counteract the aberrant gene regulation patterns observed. Data are also available on panels of cancer cell lines, which have been both profiled at the gene expression level and extensively characterized for drug responses, allowing us to identify geneto- drug correlations. Profiling tumors from patients undergoing adjuvant or neoadjuvant drug treatment can also yield markers of therapeutic response. In this review, we will examine recent studies aimed at our eventually being able to use the molecular profile of a tumor to predict drug response. The profiling data from these studies is publicly available, and can be re-examined by researchers with different questions in mind, offering us a large number of biomarker candidates that could potentially be tested in the clinical setting.
Export Options
About this article
Cite this article as:
J. Creighton Chad, Molecular Classification and Drug Response Prediction in Cancer, Current Drug Targets 2012; 13 (12) . https://dx.doi.org/10.2174/138945012803530143
DOI https://dx.doi.org/10.2174/138945012803530143 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Kappa Receptor Bivalent Ligands
Current Topics in Medicinal Chemistry Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery The Novel Multi-Target Iron Chelator, M30 Modulates HIF-1α-Related Glycolytic Genes and Insulin Signaling Pathway in the Frontal Cortex of APP/PS1 Alzheimer’s Disease Mice
Current Alzheimer Research MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience
Reviews on Recent Clinical Trials GSK-3 Inhibitors as New Leads to Treat Type-II Diabetes
Current Drug Targets Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions
Current Enzyme Inhibition Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Neuroinflammation and Neuroprotection: An Update on (Future) Neurotrophin-Related Strategies in Multiple Sclerosis Treatment
Current Medicinal Chemistry Functionalized Carbon Nano-scale Drug Delivery Systems From Biowaste Sago Bark For Cancer Cell Imaging
Current Drug Delivery Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design Theories and Treatment of Drug Dependency: A Neurochemical Perspective
Current Molecular Pharmacology Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets